Tumor-initiating cells and tumor vascularization

Pediatric Blood and Cancer

Volumn 56, Issue 3, 2011, Pages 335-340

  Zhang, Li Zhi ^a   Zhang, Chang Qing ^a   Yan, Zhen Yu ^b   Yang, Qing Cheng ^a   Jiang, Yao ^a   Zeng, Bing Fang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Affiliated Hospital of North China   (China)

Author keywords

Cancer stem cells (CSCs); Dormancy; Gene; Hypoxia; Metastasis; Tumor initiating cells (TICs); Vascular niche; Vascularity

Indexed keywords

FIBROBLAST GROWTH FACTOR; K RAS PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; VASCULOTROPIN; WNT PROTEIN;

BRAIN TUMOR; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL INTERACTION; EPIGENETICS; GENETIC REGULATION; GENOMIC INSTABILITY; HUMAN; HYPOXIA; METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR INITIATING CELL; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78651093456     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22886     Document Type: Review

References (98)

1. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
2. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
3. Kennedy JA, Barabe F, Poeppl AG, et al. Comment on "tumor growth need not be driven by rare cancer stem cells". Science 2007; 318: 1722. author reply 1722.
4. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008; 68: 4018-4021.
5. Passegue E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nat Med 2009; 15: 23.
6. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
7. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
8. Mahller YY, Williams JP, Baird WH, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009; 4: e4235.
9. Welte Y, Adjaye J, Lehrach HR, et al. Cancer stem cells in solid tumors: Elusive or illusive? Cell Commun Signal 2010; 8: 6.
10. Lewis MT. The more things change. the more things change: Developmental plasticity of tumor-initiating mammary epithelial cells. Breast Cancer Res 2010; 12: 101.
11. Bansal N, Banerjee D. Tumor initiating cells. Curr Pharm Biotechnol 2009; 10: 192-196.
12. Lewis MT. Faith, heresy and the cancer stem cell hypothesis. Future Oncol 2008; 4: 585-589.
13. Patru C, Romao L, Varlet P, et al. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010; 10: 66.
14. Clement V, Marino D, Cudalbu C, et al. Marker-independent identification of glioma-initiating cells. Nat Methods 2010; 7: 224-228.
15. Eaves CJ. Cancer stem cells: Here, there, everywhere? Nature 2008; 456: 581-582.
16. Wu XZ. Origin of cancer stem cells: The role of self-renewal and differentiation. Ann Surg Oncol 2008; 15: 407-414.
17. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
18. Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis 2010; 31: 167-174.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
20. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
21. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
22. James D, Rabbany S, Rafii S. Hitting the mother lode of tumor angiogenesis. Nat Biotechnol 2008; 26: 769-770.
23. Conway AE, Lindgren A, Galic Z, et al. A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells 2009; 27: 18-28.
24. Conway AE, Lindgren A, Galic Z, et al. A pluripotency and self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells 2009; 27: 18-28.
25. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009; 78: 1-17.
26. Felsher DW. Reversing cancer from inside and out: Oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol 2008; 6: 149-154.
27. Watnick RS, Cheng YN, Rangarajan A, et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-231.
28. Knies-Bamforth UE, Fox SB, Poulsom R, et al. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004; 64: 6563-6570.
29. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213.
30. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-1065.
31. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848.
32. Folkins C, Shaked Y, Man S, et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009; 69: 7243-7251.
33. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-5511.
34. Oka N, Soeda A, Inagaki A, et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007; 360: 553-559.
35. Garnier D, Milsom C, Magnus N, et al. Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res 2010; 125: S44-S50.
36. Veeravagu A, Bababeygy SR, Kalani MY, et al. The cancer stem cell-vascular niche complex in brain tumor formation. Stem Cells Dev 2008; 17: 859-867.
37. Hovinga KE, Shimizu F, Wang R, et al. Inhibition of Notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010; 28: 1019-1029.
38. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
39. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008; 21: 39-55.
40. Zhang LZ, Mei J, Qian ZK, et al. The role of VE-cadherin in osteosarcoma cells. Pathol Oncol Res 2010; 16: 111-117.
41. Abdollahi A, Hlatky L, Huber PE. Endostatin: The logic of antiangiogenic therapy. Drug Resist Updat 2005; 8: 59-74.
42. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
43. Eyler CE, Rich JN. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-2845.
44. Monzani E, La Porta CA. Targeting cancer stem cells to modulate alternative vascularization mechanisms. Stem Cell Rev 2008; 4: 51-56.
45. Rafii S, Lyden D. Cancer. A few to flip the angiogenic switch. Science 2008; 319: 163-164.
46. Mimeault M, Batra SK. New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today 2010; 15: 354-364.
47. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
48. Demou ZN, Hendrix MJ. Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J Cell Biochem 2008; 105: 562-573.
49. Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006; 103: 16466-16471.
50. Abdollahi A, Folkman J. Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
51. Achilles EG, Fernandez A, Allred EN, et al. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001; 93: 1075-1081.
52. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321.
53. Blagosklonny MV. Target for cancer therapy: Proliferating cells or stem cells. Leukemia 2006; 20: 385-391.
54. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
55. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846.
56. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20: 947-949.
57. Udagawa T, Fernandez A, Achilles EG, et al. Persistence of microscopic human cancers in mice: Alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361-1370.
58. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle 2006; 5: 1779-1787.
59. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431: 1112-1117.
60. Stamper IJ, Byrne HM, Owen MR, et al. Modelling the role of angiogenesis and vasculogenesis in solid tumour growth. Bull Math Biol 2007; 69: 2737-2772.
61. Wu XZ, Chen D, Xie GR. Bone marrow-derived cells: Roles in solid tumor. Minireview. Neoplasma 2007; 54: 1-6.
62. Moserle L, Amadori A, Indraccolo S. The angiogenic switch: Implications in the regulation of tumor dormancy. Curr Mol Med 2009; 9: 935-941.
63. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010; 10: 138-146.
64. Naumov GN, Folkman J, Straume O, et al. Tumor-vascular interactions and tumor dormancy. APMIS 2008; 116: 569-585.
65. Rak J, Milsom C, Yu J. Vascular determinants of cancer stem cell dormancy-Do age and coagulation system play a role? APMIS 2008; 116: 660-676.
66. Mazumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 2009; 13: 4319-4328.
67. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472.
68. Storci G, Sansone P, Mari S, et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 2010; 225: 682-691.
69. Rodriguez-Jimenez FJ, Moreno-Manzano V, Lucas-Dominguez R, et al. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. Stem Cells 2008; 26: 2052-2062.
70. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007; 67: 1-5.
71. Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009; 279: 13-21.
72. Pedersen M, Lofstedt T, Sun J, et al. Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. Biochem Biophys Res Commun 2008; 377: 98-103.
73. Han ZB, Ren H, Zhao H, et al. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 2008; 29: 1853-1861.
74. Dorevic G, Matusan-Ilijas K, Babarovic E, et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009; 28: 40.
75. Indovina P, Collini M, Chirico G, et al. Three-dimensional cell organization leads to almost immediate HRE activity as demonstrated by molecular imaging of MG-63 spheroids using two-photon excitation microscopy. FEBS Lett 2007; 581: 719-726.
76. Hellwig-Burgel T, Stiehl DP, Wagner AE, et al. Review: Hypoxia-inducible factor-1 (HIF-1): A novel transcription factor in immune reactions. J Interferon Cytokine Res 2005; 25: 297-310.
77. Liao D, Johnson RS. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26: 281-290.
78. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
79. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
80. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008; 107: 133-138.
81. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-220.
82. Wels J, Kaplan RN, Rafii S, et al. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev 2008; 22: 559-574.
83. Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009; 24: 1-39.
84. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
85. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121.
86. Yoshida S, Sukeno M, Nabeshima Y. A vasculature-associated niche for undifferentiated spermatogonia in the mouse testis. Science 2007; 317: 1722-1726.
87. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
88. Peinado H, Rafii S, Lyden D. Inflammation joins the "niche". Cancer Cell 2008; 14: 347-349.
89. Seandel M, Butler JM, Kobayashi H, et al. Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene. Proc Natl Acad Sci USA 2008; 105: 19288-19293.
90. Wicha MS. Cancer stem cells and metastasis: Lethal seeds. Clin Cancer Res 2006; 12: 5606-5607.
91. Li F, Tiede B, Massague J, et al. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
92. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
93. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479-494.
94. Nikolova G, Strilic B, Lammert E. The vascular niche and its basement membrane. Trends Cell Biol 2007; 17: 19-25.
95. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435: 969-973.
96. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005; 23: 879-894.
97. Vassilopoulos A, Wang RH, Petrovas C, et al. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci 2008; 4: 133-142.
98. Stratford AL, Reipas K, Maxwell C, et al. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med 2010; 12: e22.